MARKET

ELDN

ELDN

Eledon Pharmaceuticals Inc
NASDAQ
2.510
0.000
0.00%
Closed 13:00 11/25 EST
OPEN
2.510
PREV CLOSE
2.510
HIGH
2.510
LOW
2.510
VOLUME
59
TURNOVER
128
52 WEEK HIGH
5.32
52 WEEK LOW
2.270
MARKET CAP
34.53M
P/E (TTM)
-0.9419
1D
5D
1M
3M
1Y
5Y
BRIEF-Eledon Pharmaceuticals Reports Third Quarter 2022 Operating, Financial Results
Reuters · 11/14 21:41
Eledon Pharmaceuticals GAAP EPS of -$0.73
Seekingalpha · 11/14 21:05
Eledon Pharmaceuticals Q3 EPS $(0.73) Misses $(0.68) Estimate
Benzinga · 11/14 21:03
A Preview Of Eledon Pharmaceuticals's Earnings
Benzinga · 11/11 20:38
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Management to host conference call and webcast at 4:30 pm ETIRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter ended Sep...
GlobeNewswire · 11/03 20:05
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that the Company will present two posters at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 being held November ...
GlobeNewswire · 10/24 20:05
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A panel discussion with Steven Perrin, Ph.D., President and Chief...
GlobeNewswire · 10/03 12:00
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Confe...
GlobeNewswire · 09/22 20:05
More
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. It is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). It has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).

Webull offers kinds of Eledon Pharmaceuticals Inc stock information, including NASDAQ:ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.